TBCV92

TBCV92 is a preclinical-stage cell therapy being developed by FibroGenesis for the treatment of various cancers. The program is built upon the company's proprietary fibroblast-based platform, which utilizes human dermal fibroblasts (HDFs) as a therapeutic modality or as a delivery vector for anti-cancer payloads. By leveraging the natural homing and secretory properties of fibroblasts, TBCV92 is designed to infiltrate the tumor microenvironment and deliver therapeutic effects directly to malignancy sites. As of 2021, the asset is positioned in the preclinical phase of development, with specific molecular targets and the nature of its therapeutic payload remaining undisclosed in public documentation.